Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2017 Apr 10;16(7):1212–1223. doi: 10.1158/1535-7163.MCT-16-0690

Figure 4. In vitro anticancer activity of LL2.

Figure 4

(a) Endogenous expression of galectin-1 in six different cancer cells. (b) Death ligand LLS2 (soluble form) kills a number of different cancer cell lines in solution. (c) Immunoblots demonstrate the suppression of endogenous galectin-1 expression by siRNA in SKOV3 cells, and ectopic over-expression of galectin-1 in HT-29 cells. (d) SKOV3 cells transfected with control siRNA, galectin-1 siRNA and HT29 cells transfected with control pcDNA3.1, pcDNA/Gal-1 were treated with/without LLS2 (25 uM) for 72 hours. *p<0.05; **p <0.01; ***p <0.001